Impacting Cancer

Nextech Invest, September 2016
Is this email not displaying correctly?
View it in your browser.

Dear Reader, 

We congratulate Celgene and Jounce Therapeutics for forming a transformational strategic collaboration and welcome Cleave Biosciences to our portfolio. In an exclusive Interview, Laura Shawver, CEO of Cleave Biosciences, shares her experience in the industry and provides further background on Cleave as well as the opportunity in multiple myeloma. In the Nextech Insights, Kristina Kakalacheva reviews the current market trends in cancer therapeutics in multiple myeloma in regard to Cleave Biosciences.

With kind regards, 
The Nextech Team

Portfolio Highlight

Jounce Therapeutics and Celgene announce strategic collaboration

Jounce Therapeutics and Celgene (NASDAQ:CELG) announced a global strategic collaboration in July 2016 focusing on the development and commercialization of innovative immuno-oncology treatments. The deal involves an upfront payment of USD 225 million and an equity investment of USD 36 million. In addition, the deal terms cover consecutive milestone payments of up to USD 2.3 billion for the lead candidate JTX-2011 and up to four additional programs. Jounce Therapeutics will share US rights for all programs and receive tiered royalties on ex-US sales.

Read the press release

Portfolio News

Nextech Invest welcomes Cleave Biosciences to the portfolio

Cleave Biosciences closed a USD 37 million Series B round in August 2016 financing with the participation of new investors Celgene and Nextech Invest. Cleave is a leader in the discovery and development of drugs targeting protein homeostasis and is using the proceeds to advance the clinical development of CB-5083. 

Read the press release


Introducing Laura Shawver, CEO of Cleave Biosciences

Laura Shawver, PhD, CEO of Cleave Biosciences, is a biotech executive with more than 25 years of experience at SUGEN and Phenomix among others. She is also an ovarian cancer survivor and founder of the Clearity Foundation. In this exclusive interview she introduces Cleave Biosciences, the latest addition to Nextech's portfolio, and shares her perspective on the development of cancer drugs.

Read the interview

 Nextech Insights

Multiple Myeloma Market Dynamics

In connection to the activities of Nextech's latest portfolio company Cleave Biosciences in multiple myeloma, Kristina Kakalacheva, PhD, reviews the therapeutic advances and dynamics of this market with large unmet medical need in this Nextech Insights.

Read the article.

Kura Oncology 
(NASDAQ:KURA) has released preliminary data on an ongoing Phase II clinical trial of tipifarnib in HRAS mutant solid tumors showing positive activity, including objective responses.

Read the press release

Peloton Therapeutics completes USD 52.4 million private financing.

Read the press release

Jounce Therapeutics initiated a clincial Phase I/II study of JTX­-2011 in patients with advanced solid tumors.

Read the press release.

Blueprint Medicines (NASDAQ:BPMC) announced a new drug discovery program targeting PRKACA kinase fusions for the treatment of fibrolamellar carcinoma.

Read the press release.  

Sunesis Pharmaceuticals (NASDAQ:SNSS) presented positive results from MD Anderson Cancer Center sponsored trial in frontline elderly AML and MDS and clinical data from the Phase Ia dose-escalation study of the BTK-inhibitor SNS-062.

Read the press releases.


Nextech Invest Ltd.
Turnerstrasse 26
8006 Zurich, Switzerland